Use of cidofovir in pediatric patients with adenovirus infection [version 2; referees: 3 approved]

Abstract

Adenoviruses contribute to morbidity and mortality among Background immunocompromised pediatric patients including stem cell and solid organ transplant recipients. Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompromised patients despite concern of potential nephrotoxicity… (More)

Topics

4 Figures and Tables

Cite this paper

@inproceedings{ORyan2017UseOC, title={Use of cidofovir in pediatric patients with adenovirus infection [version 2; referees: 3 approved]}, author={Miguel L. O’Ryan and Jeffrey M. Bergelson and David A Hunstad and Andrew Janowski and Lakshmi Ganapathi and Ofer Levy}, year={2017} }